Reading ATRA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ATRA free→Reading ATRA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ATRA free→QuarterlyIQ Insights · ATRA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 11, 2026, the Board of Directors (the “ Board ”) of Atara Biotherapeutics, Inc. (the “ Company ”) appointed Brian Cherry to serve as a member of the Board as a Class I director, effective June 11, 2026 (the “ Effective Date ”). Mr. Cherry was also appointed to the Audit Committee of the Board. The Board has determined that Mr. Cherry is ind…
and in the press release included as Exhibit 99.1 shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended, and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such fi…
Other Events. On May 7, 2026, Atara Biotherapeutics, Inc. (the “Company”) issued a press release titled “Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel” providing an update following the Type A meeting with the U.S. Food and Drug Administration (the “FDA”) to discuss the Complete Response Letter for the EBVALLO™ Biologics License Application issued on January 9, 2026. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference into this
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 30, 2026, Atara Biotherapeutics, Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company no longer meets Nasdaq’s $50 million minimum market value for listed securities (“MVLS”) requirement pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requ…
and in the press release included as Exhibit 99.1 shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended, and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such fi…
Other Events. On March 12, 2026, Atara Biotherapeutics, Inc. (the “Company”) issued a press release titled “Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel” announcing that the Type A meeting with the U.S. Food and Drug Administration (the “FDA”) to discuss the Complete Response Letter for the EBVALLO™ Biologics License Application issued on January 9, 2026 has been scheduled. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference into…
Other Events. On March 3, 2026, Atara Biotherapeutics, Inc. (the “Company”) issued a press release titled “Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel” announcing that Pierre Fabre Pharmaceuticals, Inc. has submitted a request for a Type A meeting with the U.S. Food and Drug Administration (the “FDA”) to discuss the plan to address the issues raised by the FDA in the Complete Response Letter for the EBVALLO ™ Biologics License Application issued on January 9, 2026. A cop…
The Company issued the Warrant pursuant to the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”) available under Section 4(a)(2) of the Securities Act. Pursuant to the terms of the Warrant, the Company intends to file a registration statement relating to the resale of the Company’s Common Stock underlying the Warrant, subject to the registration rights provisions of the Warrant.
Entry into a Material Definitive Agreement. On February 20, 2026, Atara Biotherapeutics, Inc., (the “Company”) entered into an Amendment (the “Amendment”) to the Purchase and Sale Agreement dated as of December 20, 2022 (the “Agreement”) with HCR Molag Fund, L.P. (“HCR”). Under the terms of the Amendment, HCR agreed to amend the due date of the one-time of $9.0 million cash payment associated with the achievement of a certain milestone within the Amended and Restated Commercialization Agreeme…
Results of Operations and Financial Condition. In connection with the press release described in
Entry into a Material Definitive Agreement. On December 30, 2025, Atara Biotherapeutics, Inc., (the “Company”) entered into the Fourth Amendment (the “Amendment”) to the Amended and Restated Commercialization Agreement dated October 31, 2023 (the “Agreement”) with Pierre Fabre Medicament (“Pierre Fabre”). Under the terms of the Amendment, the Company has agreed to reduce the aggregate amount of potential milestone payments payable by Pierre Fabre to the Company upon achieving certain regulato…
and in the press release included as Exhibit 99.1 shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended, and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such fi…
Costs Associated with Exit or Disposal Activities. On October 6, 2025, Atara Biotherapeutics, Inc. (the “Company”) announced a reduction in its workforce that will impact approximately 29% of its current employees, retaining approximately 15 employees essential to executing on the Company’s strategic priorities. The Company expects to complete the workforce reduction by January 2026. The Company expects to recognize approximately $1.3 million for severance and related benefits for employees l…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) Following an assessment by the Board of Directors (the “Board”) of Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”), of its size and composition, the Board determined that a reduction in the number of directors would help right-size the Board to reflect the Company's current operations and further align the size of the Compan…
and in the press release included as Exhibit 99.1 shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended, and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such fi…
Results of Operations and Financial Condition. In connection with the press release described in
Other Events. On May 14, 2024, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, as representative (the “Representative”) of the underwriters (the “Underwriters”) named therein, pursuant to which the Company agreed to issue and sell to the Underwriters in an underwritten registered direct offering (the “Offering”) an aggregate of (i) 834,237 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Comm…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. In connection with the Company’s offer and sale of 834,237 shares of common stock at an offering price of $6.61 per share and pre-funded warrants to purchase 1,587,108 shares of common stock at an offering price of $6.6099 per share in an underwritten registered direct offering to a limited number of existing institutional investors, including enti…
and in the press release included as Exhibit 99.1 of this current report on Form 8-K shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended, and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission (the “SEC”), whether made before or after the date hereof, except as shall be expre…
Costs Associated with Exit or Disposal Activities. On May 12, 2025, Atara Biotherapeutics, Inc. (the “Company”) announced a reduction in its workforce that will impact approximately 30% of its current employees, retaining approximately 23 employees essential to executing on the Company’s strategic priorities. The Company expects to complete the workforce reduction by August 2025. The Company expects to recognize approximately $1.4 million for severance and related benefits for employees laid…
Other Events. On May 5, 2025, Atara Biotherapeutics, Inc. (the “Company”) issued a press release titled “Atara Biotherapeutics Provides Regulatory Updates on EBVALLO ™ (tabelecleucel)” announcing that the U.S. Food and Drug Administration (“FDA”) lifted the clinical hold on the Company’s active Investigational New Drug applications for the EBVALLO ™ (tabelecleucel) program that was placed in January 2025. The press release also announced that the FDA granted the Company a Type A meeting to di…
Entry into a Material Definitive Agreement. On March 31, 2025, Atara Biotherapeutics, Inc., (the “Company”) entered into an Amendment (the “Amendment”) to the Amended and Restated Commercialization Agreement dated October 31, 2023 (the “Agreement”) with Pierre Fabre Medicament (“Pierre Fabre”). Under the terms of the Amendment, as of March 31, 2025, the Company has completed the transfer of all manufacturing responsibility to Pierre Fabre and Pierre Fabre will be, at its cost, responsible for…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On March 25, 2025, it was agreed that the employment of Eric Hyllengren, the Chief Financial Officer and Chief Operating Officer of Atara Biotherapeutics, Inc. (the “ Company ”), would end effective March 31, 2025. In connection with Mr. Hyllengren’s departure from the Company, Mr. Hyllengren is entitled to receive, subject to a general release…
and in the press release included as Exhibit 99.1 shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended, and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such fi…
Costs Associated with Exit or Disposal Activities. On March 3, 2025, the Company announced a reduction in its workforce that will impact approximately 50% of its current employees following the Company’s decision to discontinue all development activities for ATA3219 and ATA3431, including all CAR T clinical studies evaluating ATA3219 and pause both ATA3219 and ATA3431 programs. The Company expects to substantially complete the workforce reduction by June 2025. The Company expects to recognize…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.